Kevin Waters, Executive Vice President and CFO of PROCEPT BioRobotics Corp (NASDAQ:PRCT), filed a Form 4 on August 14, 2026, disclosing the acquisition of restricted stock units and a stock option grant dated August 13, 2026.

Key Highlights

  • RSU grant: Waters acquired 29,527 restricted stock units at a price of $0, each representing a contingent right to receive one share of Common Stock.
  • Stock option grant: Waters acquired a stock option to purchase 40,851 shares of Common Stock at an exercise price of $21.95, expiring August 12, 2036.
  • Post-transaction ownership: Waters directly holds 180,728 shares of Common Stock following the reported RSU acquisition.
  • RSU vesting schedule: One-quarter of the RSUs vest on August 13, 2027, with one-sixteenth of the remaining RSUs vesting quarterly over 36 months, subject to continued service.
  • Option vesting schedule: 1/48th of the stock option shares vest monthly from August 13, 2026, over a four-year period, subject to continued employment or service.
  • Advance grant structure: According to the filing, both grants "are intended to be 50% of the value of the Reporting Person's expected 2027 grant, and made in lieu of such portion of the expected 2027 grant."

PROCEPT BioRobotics CFO Kevin Waters Receives Equity Grants Described as Partial 2027 Award

According to the Form 4 filed with the SEC on August 14, 2026, Kevin Waters, serving as EVP and CFO of PROCEPT BioRobotics Corp, received two equity awards on August 13, 2026. The first was a grant of 29,527 restricted stock units (RSUs) acquired at $0, with each RSU representing a contingent right to receive one share of Common Stock. Following this transaction, Waters directly held 180,728 shares of Common Stock, the filing disclosed.

The RSU vesting schedule, as described in the filing's footnotes, calls for one-quarter of the units to vest on August 13, 2027, with one-sixteenth of the remaining units vesting quarterly over the subsequent 36 months, contingent on Waters continuing as a service provider through each applicable date. The second grant is a stock option carrying the right to purchase 40,851 shares of Common Stock at an exercise price of $21.95 per share, with an expiration date of August 12, 2036. The option vests at a rate of 1/48th of the total shares monthly, beginning from a vesting commencement date of August 13, 2026, over four years, subject to continued employment or service.

The filing notes that both the RSU grant and the stock option grant "are intended to be 50% of the value of the Reporting Person's expected 2027 grant, and made in lieu of such portion of the expected 2027 grant." The Form 4 was signed by Jonathan Stone as Attorney-in-Fact for Kevin Waters and filed on August 14, 2026. Both grants are held directly by Waters.

What Was Disclosed

The filing reports two equity awards to PROCEPT BioRobotics CFO Kevin Waters: 29,527 RSUs and a stock option for 40,851 shares at $21.95, both dated August 13, 2026, and both described as representing 50% of his expected 2027 grant made in advance.